Brief: Angiodynamics Announces Two-Year Preserve Trial Data Demonstrating Durable Nanoknife Ire System Outcomes In Intermediate-Risk Prostate Cancer
13/05/2026 14:06
May 13 (Reuters) - AngioDynamics Inc ANGO.O: ANGIODYNAMICS ANNOUNCES TWO-YEAR PRESERVE TRIAL DATA DEMONSTRATING DURABLE NANOKNIFE IRE SYSTEM OUTCOMES IN INTERMEDIATE-RISK PROSTATE CANCER Source text: ID:nBw52RLK2a Further company coverage: ANGO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AngioDynamics
See all newsAngioDynamics, Inc. reports results for the quarter ended August 31 - Earnings Summary
AngioDynamics Q1 sales beat on med tech segment growth
AngioDynamics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
AngioDynamics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
AngioDynamics Inc reports results for the quarter ended May 31 - Earnings Summary